News · 26 weeks73+14%
2026-04-192026-10-11
Mix3090d
- Insider14(47%)
- SEC Filings8(27%)
- Other4(13%)
- Earnings2(7%)
- Leadership1(3%)
- Analyst1(3%)
Latest news
25 items- PRIllumina launches BioInsight Platform, its first unified software environment to help accelerate genomic and multiomic breakthroughsThe new platform brings together advanced analysis, purpose-built AI, and curated biological data so researchers can move more quickly from complex genomic and multiomic data to actionable insightIncluded in the new platform, latest DRAGEN update expands access to Illumina's award-winning secondary analysis across supported cloud and standard computing environmentSAN DIEGO, Oct. 14, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today debuted the Illumina BioInsight Platform, the company's first unified software environment designed to help researchers turn complex genomic and multiomic data into meaningful biological evidence. By bringing together Illumina's analysis applications, purpos
- SECSEC Form 8-K filed by Illumina Inc.8-K - ILLUMINA, INC. (0001110803) (Filer)
- PRIllumina to Announce Third Quarter 2026 Financial Results on Thursday, October 29, 2026SAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the third quarter 2026 following the close of market on Thursday, October 29, 2026.On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results.Conference Call DetailsThe conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, October 29, 2026. Interested parties may access the live webcast via the Investor Info section of Illumina's
- PRIllumina releases SpliceAI2 to help advance rare disease researchIn a rare disease research dataset, SpliceAI2 identified 17% more disease-relevant variants compared to other splicing modelsIllumina's genomic AI models now collectively enable researchers to identify 2x as many variants with predicted biological impactSAN DIEGO, Oct. 8, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today introduced SpliceAI2, a new genomic AI model designed to address one of the central challenges in genomics: understanding the functional consequences of genetic variation. SpliceAI2 helps researchers identify disease-relevant splice variants that otherwise may go unnoticed. Predicting splice effects is key to resolving variants of uncertain significance in rare disease
- INSIDERSEC Form 4 filed by Illumina Inc.4 - ILLUMINA, INC. (0001110803) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Illumina Inc.SCHEDULE 13G - ILLUMINA, INC. (0001110803) (Subject)
- INSIDERDirector Meister Keith A. was granted 107 shares, increasing direct ownership by 2% to 6,887 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERDirector Ullem Scott B. was granted 113 shares, increasing direct ownership by 1% to 11,143 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERChief Legal Officer Coletti Julie Ann was granted 18,763 shares (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERSVP, Chief Technology Officer Barnard Steven covered exercise/tax liability with 408 shares, decreasing direct ownership by 0.99% to 40,927 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- ANALYSTUBS resumed coverage on Illumina with a new price targetUBS resumed coverage of Illumina with a rating of Buy and set a new price target of $260.00
- PRBloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600NEW YORK, Sept. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 21, 2026, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective Date Index Name Action Company Name Ticker GICS Sector Sept 21, 2026 S&P 100AdditionDell Techno
- INSIDERDirector Meister Keith A. sold $57,199,201 worth of shares (263,560 units at $217.03) (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- PRThe Market Just Told You Which Layer Of AI Biology It Is Paying ForAUSTIN, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Market Updates News Commentary - Earnings season in life sciences technology has just delivered an unusually clean verdict. The company that owns the industry’s data and systems of record beat and jumped. The company selling model-informed software into the same customers missed and fell by roughly the same amount on the day. The AI-native discovery company reported a fraction of the revenue analysts expected. Read together, those three results say something specific about where value is accruing in AI-enabled drug discovery, and it is not where most of the narrative has been pointed. Companies mentioned in today’s commentary include: Mind
- INSIDERDirector Meister Keith A. sold $85,241,664 worth of shares (375,941 units at $226.74) (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERDirector Meister Keith A. sold $145,556,398 worth of shares (679,574 units at $214.19) (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- INSIDERSVP, Strategy/Corp Development Wedel Christensen Jakob sold $197,840 worth of shares (1,033 units at $191.52), decreasing direct ownership by 7% to 14,023 units (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- SECSEC Form 8-K filed by Illumina Inc.8-K - ILLUMINA, INC. (0001110803) (Filer)
- SECIllumina Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - ILLUMINA, INC. (0001110803) (Filer)
- SECSEC Form 8-K filed by Illumina Inc.8-K - ILLUMINA, INC. (0001110803) (Filer)
- INSIDERSEC Form 3 filed by new insider Coletti Julie Ann3 - ILLUMINA, INC. (0001110803) (Issuer)
- SECSEC Form FWP filed by Illumina Inc.FWP - ILLUMINA, INC. (0001110803) (Subject)
- INSIDERChief Commercial Officer Sullivan Michael C was granted 4,503 shares (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
- SECIllumina Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - ILLUMINA, INC. (0001110803) (Filer)
- INSIDERDirector Meister Keith A. sold $148,159,897 worth of shares (741,127 units at $199.91) (SEC Form 4)4 - ILLUMINA, INC. (0001110803) (Issuer)
ILMN FAQ
7 questionsWhat does Illumina Inc. do?
Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic...Where does ILMN stock trade?
Illumina Inc. (ILMN) is listed on NASDAQ.What sector and industry is ILMN in?
Illumina Inc. operates in the Health Care sector, Medical Specialities industry.When did Illumina Inc. go public?
Illumina Inc. (ILMN) completed its IPO in 2000.What are analysts saying about ILMN?
Illumina Inc. has had 8 recent analyst actions on file. The most recent action was from UBS: Buy on 2026-09-09.What companies are similar to ILMN?
Notable peers in the same industry include TMO (Thermo Fisher Scientific Inc), QGEN (Qiagen N.V.), TXG (10x Genomics Inc.). Compare ILMN side-by-side with any of them on Quantisnow.How can I track ILMN on Quantisnow?
Quantisnow aggregates Illumina Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ILMN to receive live email and push alerts on every new disclosure.